Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 5/20 | 0.69 |
| ▸ | LMNA | P02545 | 8/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.69 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.69 |
| ▸ | TSHR | P16473 | 5/20 | 0.69 |
| ▸ | SHBG | P04278 | 5/20 | 0.69 |
| ▸ | SERPINA6 | P08185 | 5/20 | 0.69 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.69 |
| ▸ | MAPT | P10636 | 4/20 | 0.69 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.69 |
| ▸ | SNCA | P37840 | 4/20 | 0.69 |
| ▸ | NR3C1 | P04150 | 3/20 | 0.69 |
| ▸ | PGR | P06401 | 3/20 | 0.69 |
| ▸ | AR | P10275 | 3/20 | 0.69 |
| ▸ | GPBAR1 | Q8TDU6 | 3/20 | 0.69 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.69 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.69 |
| ▸ | CYP51A1 | Q16850 | 2/20 | 0.69 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3373116 | 1.00 | CYP17A1 (0.69) | CYP17A1LMNACYP3A4HSD17B10TSHR | |
| SCHEMBL3748842 | 1.00 | CYP17A1 (0.69) | CYP17A1LMNACYP3A4HSD17B10TSHR | |
| SCHEMBL8994128 | 0.89 | LMNA (0.70) | CYP17A1LMNACYP3A4HSD17B10TSHR | |
| Itruvone SCHEMBL18708951 | 0.88 | LMNA (0.69) | CYP17A1LMNACYP3A4HSD17B10TSHR | |
| Itruvone SCHEMBL15853688 | 0.88 | LMNA (0.69) | CYP17A1LMNACYP3A4HSD17B10TSHR | |
| Itruvone SCHEMBL6819079 | 0.88 | LMNA (0.69) | CYP17A1LMNACYP3A4HSD17B10TSHR | |
| SCHEMBL8369956 | 0.87 | LMNA (0.67) | CYP17A1LMNACYP3A4HSD17B10TSHR | |
| SCHEMBL8369957 | 0.87 | LMNA (0.67) | CYP17A1LMNACYP3A4HSD17B10TSHR | |
| SCHEMBL10929607 | 0.86 | LMNA (0.66) | CYP17A1LMNACYP3A4HSD17B10TSHR | |
| SCHEMBL10929618 | 0.86 | LMNA (0.66) | CYP17A1LMNACYP3A4HSD17B10TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100292184-A1 | 17BETA-CYANO-19-ANDROST-4-ENE DERIVATIVE, ITS USE AND MEDICAMENTS COMPRISING THE DERIVATIVE | BAYER SCHERING PHARMA AG (DE) | 2010-11-18 | — | — | US | disclosed |
| WO-2010066349-A1 | USE OF 17BETA-CYANO-19-ANDROST-4-ENE DERIVATIVES FOR MANUFACTURING A MEDICAMENT IN A SUSTAINED-RELEASE FORM FOR PARENTERAL USE, AND SUSTAINED-RELEASE MEDICAMENT CONTAINING 17BETA-CYANO-19-ANDROST-4-ENE DERIVATIVES FOR PARENTERAL USE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-06-17 | — | — | WO | disclosed |
| WO-2008152112-A2 | 17ß-CYANO-19-ANDROST-4-ENE DERIVATIVE, USE THEREOF AND MEDICAMENTS CONTAINING SAID DERIVATIVE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292184-A1 | 17BETA-CYANO-19-ANDROST-4-ENE DERIVATIVE, ITS USE AND MEDICAMENTS COMPRISING THE DERIVATIVE | HSD17B11, HSD17B7, NR5A1 | CYP17A1 4/4885LMNA 3030/4885CYP3A4 166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.